Shift your goal on purpose
While you are losing weight, a falling number shows progress. In maintenance, a stable number is the goal. Agree a realistic weight range and health goals with your prescriber. Normal ups and downs then do not prompt needless dose changes or worry.
Your treatment record should keep your original measurements and the reason for treatment. If your BMI falls on successful treatment, you are in a different position from someone asking to start at that BMI. A written history helps a new clinician follow the reasoning.
What the evidence on continuing treatment shows
STEP 4 compared carrying on with semaglutide against stopping after a first treatment period, with lifestyle support continuing in both groups. People who stayed on treatment kept weight off better than those switched to placebo. STEP 5 also showed average benefit held over two years.
These trials support treating obesity as a long-term condition, which may need ongoing treatment. They do not set one lifelong plan for everyone. Side effects, changing health, pregnancy plans, access and your own goals still need review. The evidence for standard weekly dosing is stronger than for stretching the gap between doses on your own.
Check your nutrition
Holding a lower weight, you still need enough food, protein, fibre, vitamins and minerals. Ongoing trouble eating, weakness, repeated dizziness or weight loss you do not want all need attention. Feeling no hunger does not mean your body needs less nutrition.
Keep active in ways that build function and strength, adapted to any disability, pain or other condition. Choose routines you enjoy. Exercise should not become a way to pay for food. Ask for dietitian support if planning meals becomes hard or too restrictive.
Know the service and funding limits
NICE TA875 sets a maximum two-year course in specialist weight-management care. That is a funding recommendation for one NHS pathway. The product licence has no rule that semaglutide must always stop at two years. Heart risk treatment follows separate guidance, and private services set their own scope and policies.
Before you start, ask how the provider handles maintenance, a lower current BMI, dose reviews and transfer of care. A service happy to start your prescription may not offer follow-up for good. Find out those limits early, before your next supply is due.
Plan for changes
Agree how often you will review, what to do about weight loss you do not want or weight regain, and who checks your other medicines as your health changes. If cost or access puts treatment at risk, raise it early. Unplanned gaps can lower your tolerance and change the safest restart dose.
Spacing injections further apart or counting clicks has no evidence behind it as a maintenance plan. If a clinician suggests an off-label approach, ask about the reasoning, the uncertainty and how you will be monitored. A good maintenance plan explains why treatment carries on, how you will measure benefit and when another approach would suit you better.
Sources
Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.
- Wegovy FlexTouch UK prescribing information medicines.org.uk
- NICE TA875: semaglutide for weight management nice.org.uk
- STEP 5: two-year semaglutide trial pubmed.ncbi.nlm.nih.gov
- STEP 4 continued treatment and withdrawal trial pubmed.ncbi.nlm.nih.gov
Spotted something out of date? Report a mistake.